Skip to main content
SpringerLink
Log in

Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml

  • Original Article
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

To assess the diagnostic efficacy of prostate-specific antigen (PSA)-related parameters, using a total of 226 patients with gray zone PSA who underwent prostate biopsy, various cutoff points of free to total ratio of PSA (f/t PSA) and PSA velocity (PSAV) were evaluated. Higher cutoff points of f/t PSA resulted in high sensitivity and negative predictive value (NPV): at f/t PSA <15%, sensitivity was 82.0% (41/50) and NPV 84.7% (50/59), and at f/t PSA <20%, 96.0% (48/50) and 92.3% (24/26). Lowering cutoff points also resulted in higher sensitivity and NPV: at PSAV ≥0.75 ng/ml per year, sensitivity was 71.4% (15/21) and NPV 82.4% (28/34), and at PSAV ≥0.40 ng/ml per year, 95.2% (20/21) and 95.2% (20/21). Further, among the patients with both of these parameters available, both sensitivity and NPV achieved 100% (10/10 and 7/7) when the indication for biopsy was determined as f/t PSA <15% or PSAV ≥0.40 ng/ml per year. Our results showed that unnecessary prostate biopsies could be more effectively avoided among patients with “gray zone PSA” by combination of f/t PSA and PSAV than single usage of these indexes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Partin AW, Oesteling JE (1994) The clinical usefulness of prostate specific antigen: update. J Urol 152:1358–1368

    PubMed  CAS  Google Scholar 

  2. Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenoxarcinoma of the prostate. N Engl J Med 317:909–916

    Article  PubMed  CAS  Google Scholar 

  3. Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161

    Article  PubMed  CAS  Google Scholar 

  4. Catalona WJ, Richie JP, Ahmann FR et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151:1283–1290

    PubMed  CAS  Google Scholar 

  5. Partin AW, Oesterling JE (1996) The clinical usefulness of percent free prostate-specific antigen. Urology 48(6A Suppl):1–87

    Article  PubMed  CAS  Google Scholar 

  6. Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease: a prospective multicenter clinical trial. JAMA 279:1542–1547

    Article  PubMed  CAS  Google Scholar 

  7. Catalona WJ, Southwick PC, Slawin KM et al (2000) Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56:255–260

    Article  PubMed  CAS  Google Scholar 

  8. Beduschi MC, Oesteling JE (1997) Prostate-specific antigen density. Urol Clin North Am 24:323–332

    Article  PubMed  CAS  Google Scholar 

  9. Carter HB, Pearson JD (1997) Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 24:333–338

    Article  PubMed  CAS  Google Scholar 

  10. Djavan B, Remzi M, Zlotta AR et al (1999) Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol 5:71–76

    PubMed  CAS  Google Scholar 

  11. Djavan B, Remzi M, Zlotta A et al (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20:921–929

    Article  PubMed  Google Scholar 

  12. Beduschi MC, Oesteling JE (1998) Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology 51(5A Suppl):98–109

    Article  PubMed  CAS  Google Scholar 

  13. Djavan B, Zlotta AR, Byttebier G et al (1998) Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160:411–419

    Article  PubMed  CAS  Google Scholar 

  14. Bangma CH, Rietbergen JB, Kranse R et al (1997) The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 157:2191–2196

    Article  PubMed  CAS  Google Scholar 

  15. Morote J, Raventos CX, Lorente JA et al (1997) Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml. J Urol 158:502–504

    Article  PubMed  CAS  Google Scholar 

  16. Zlotta AR, Djavan B, Petein M et al (1998) Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol 160:2089–2095

    Article  PubMed  CAS  Google Scholar 

  17. Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220

    Article  PubMed  CAS  Google Scholar 

  18. Mettlin C, Littrup PJ, Kane RA et al (1994) Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project Cancer 74:1615–1620

    Article  PubMed  CAS  Google Scholar 

  19. Smith DS, Catalona WJ (1994) Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152:1163–1167

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan

    Shingo Yamamoto, Takuo Maruyama, Nobuyuki Kondoh, Michio Nojima, Hidekazu Takiuchi & Hiroki Shima

  2. Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Seiichi Hirota

Authors
  1. Shingo Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takuo Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuyuki Kondoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michio Nojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hidekazu Takiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiichi Hirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Shima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shingo Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, S., Maruyama, T., Kondoh, N. et al. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml. Int Urol Nephrol 40, 85–89 (2008). https://doi.org/10.1007/s11255-007-9236-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-007-9236-4

Keywords

Search

Navigation